ÁM

Á. Montero

HM Hospitales

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

R. Ciérvide

Hospital Universitario HM Sanchinarro

O. Hernando

HM Hospitales

M. García-Aranda

HM Hospitales

Carmen Rubio

HM Hospitales

J. Valero

HM Hospitales

M. López

HM Hospitales

P. Fernández-Letón

HM Hospitales

Meritxell Arenas

Hospital Universitari Sant Joan de Reus

BÁ

Beatriz Álvarez

HM Hospitales

D. Zucca

HM Hospitales

Cooperative Institutions

HM Hospitales

101

Hospital Universitario HM Sanchinarro

Hospital Universitario Ramón y Cajal

Hospital Universitario Fundación Jiménez Díaz

Universidad Complutense de Madrid

Instituto de Salud Carlos III

Universidad Autónoma de Madrid

Universitat Autònoma de Barcelona

Hospital Universitari Sant Joan de Reus

Hospital General Universitario Gregorio Marañón

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer

Radiotherapy and Oncology (2015)

Birgitte Vrou Offersen Liesbeth Boersma Carine Kirkove S. Hol M.C. Aznar

Guideline

Radiation oncologist

Consensus conference

10.1016/j.radonc.2014.11.030

Cite

Citations (585)

Diagnosis and locoregional treatment of patients with breast cancer during the COVID-19 pandemic/ Diagnóstico y tratamiento locorregional de las pacientes con cáncer de mama durante la pandemia de la COVID-19

Ricardo Pardo Manel Algara M. Angeles Montero-Fernandez X. Sanz Mar Vernet

We are facing a pandemic that is going to affect a significant part of the population. At the end of April in the world there are about 3,000,000 cases, with 205,000 deaths and 860,000 patients recovered. The response to this pandemic has in many cases led to a significant change in the daily work of caring for cancer patients, the good results of which depend largely on time-adjusted protocols and multidisciplinary treatments. We present a review of local, surgical and radiotherapy treatment together with authors’ recommendations made from personal experience on ways to act in the diagnosis and surgical treatment of breast cancer during the COVID-19 pandemic. The multidisciplinary Breast Committees must continue to meet weekly in videoconference format. All surgical actions and irradiations must be carried out with maximum safety for both the patients and the participating teams. Hypofractionation in radiation therapy should be the standard treatment. Sometimes it is recommended to apply a primary systemic treatment or even a primary irradiation. Great coordination between the surgical and oncology teams, both medical and radiotherapeutic, is essential.

Pandemic

Radiation oncology

Source

Cite

Citations (0)

Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia

Antioxidants (2022)

Elisabet Rodríguez‐Tomàs Johana C. Acosta L. Torres-Royo Gabriel de Febrer Gerard Baiges‐Gayà

The aim of our study was to investigate the changes produced by low-dose radiotherapy (LDRT) in the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in patients with COVID-19 pneumonia treated with LDRT and their interactions with clinical and radiological changes. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 30 patients treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as PON1-related variables, cytokines, and radiological parameters were analyzed before LDRT, at 24 h, and 1 week after treatment. Twenty-five patients (83.3%) survived 1 week after LDRT. Respiratory function and radiological images improved in survivors. Twenty-four hours after LDRT, PON1 concentration significantly decreased, while transforming growth factor beta 1 (TGF-β1) increased with respect to baseline. One week after LDRT, patients had increased PON1 activities and lower PON1 and TGF-β1 concentrations compared with 24 h after LDRT, PON1 specific activity increased, lactate dehydrogenase (LDH), and C-reactive protein (CRP) decreased, and CD4+ and CD8+ cells increased after one week. Our results highlight the benefit of LDRT in patients with COVID-19 pneumonia and it might be mediated, at least in part, by an increase in serum PON1 activity at one week and an increase in TGF-β1 concentrations at 24 h.

Paraoxonase

10.3390/antiox11061184

Cite

Citations (9)

A dose-response relationship exists for soft tissue sarcomas of the extremities treated with maximum surgery and intraoperative electron therapy, with or without external beam radiotherapy: Results of a multicentric pooled analysis

Reports of Practical Oncology & Radiotherapy (2013)

Alfredo Polo A. Álvarez Á. Montero R. Hernánz C. González-sansegundo

External beam radiotherapy

External beam radiation

10.1016/j.rpor.2013.03.575

Cite

Citations (0)

EP-1294: Accelerated partial breast irradiation (APBI) with SBRT and Gating in early breast cancer patients

Radiotherapy and Oncology (2018)

R. Ciérvide Á. Montero M. García-Aranda Mario Lopez J. Valero

10.1016/s0167-8140(18)31604-9

Cite

Citations (0)

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

R. Ciérvide Á. Montero Eduardo García‐Rico M. García-Aranda Mercedes Herrero

Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation is delivered concomitantly during the first 3 weeks of chemotherapy, and it is based on a 15 fractions scheme (40.5Gy/2.7Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy is based on Pertuzumab-Trastuzumab-Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. 58 patients were enrolled, 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved &gt;90% loss of invasive carcinoma cell in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype respectively achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies are applied simultaneously: fractionation of RT in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.

Pertuzumab

Chemoradiotherapy

Neoadjuvant Therapy

10.20944/preprints202208.0488.v1

Cite

Citations (3)

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish …

Clinical & Translational Oncology (2018)

Agustí Barnadas M. Algara Octavi Córdoba Ana Casas Miguel A. Llaneza González

Guideline

10.1007/s12094-017-1822-z

Cite

Citations (0)

Moderate hypofractionated radiation therapy and pathologic response for soft tissue sarcomas (STS) of limbs and trunk: experience from a tertiary cancer center

Clinical & Translational Oncology (2023)

Á. Montero Xin Chen-Zhao R. Ciérvide Beatriz Álvarez Alejandro Prado

Univariate analysis

10.1007/s12094-023-03237-y

Cite

Citations (4)

Intraoperative radiotherapy-containing multidisciplinary management of trunk-wall soft-tissue sarcomas

Clinical & Translational Oncology (2014)

Claudio V. Sole Felipe A. Calvo Mauricio Cambeiro Alfredo Polo Á. Montero

Intraoperative radiotherapy

Surgical margin

External beam radiotherapy

Primary tumor

10.1007/s12094-014-1157-y

Cite

Citations (8)

F2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes

Kidney International (2000)

Á. Montero Karen A. Munger Rizwan Z. Khan José Manuel Valdivielso J MORROW

F₂-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes.

Background

The recently discovered arachidonic acid derivatives, isoprostanes, are increased in pathological conditions associated with oxidative stress, such as diabetes. No role has yet been described for isoprostanes during the development of diabetic nephropathy. Cell culture in high ambient glucose has been used as a model in elucidating cellular mechanisms underlying diabetic nephropathy. Among the growth factors involved in the effect of high glucose, transforming growth factor-β (TGF-β) has been described as playing a key role in the development of nephropathy.

Methods

Streptozotocin-induced diabetic rats were supplemented in their diet with the antioxidant vitamin E (1000 U/kg diet). Blood and urine samples were taken to determine renal function and isoprostane concentration, as determined by gas chromatography/mass spectrometry. Glomerular mesangial and endothelial cells were cultured in high ambient glucose to determine the synthesis of isoprostanes and the role of isoprostanes in high glucose-induced synthesis of TGF-β.

Results

Streptozotocin-induced diabetic rats had marked increases in plasma levels and urinary excretion rates of F₂-isoprostanes. Dietary supplementation with vitamin E normalized (plasma) and reduced (urine) isoprostane levels and, surprisingly, improved proteinuria and blood urea nitrogen (BUN) levels. High ambient glucose increased F₂-isoprostane synthesis in glomerular endothelial and mesangial cells in culture. Incubation of glomerular cells with F₂-isoprostanes stimulated the production of TGF-β.

Conclusions

Increased F₂-isoprostane synthesis during diabetes appears to be responsible in part for the increase in renal TGF-β, a well-known mediator of diabetic nephropathy.

Isoprostanes

Mesangial cell

10.1111/j.1523-1755.2000.00368.x

Cite

Citations (107)